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Abstract
The human leukocyte antigen (HLA) is key to many aspects of human physiology and medicine. All current sequence-
based HLA typing methodologies are targeted approaches requiring the amplification of specific HLA gene segments.
Whole genome, exome and transcriptome shotgun sequencing can generate prodigious data but due to the
complexity of HLA loci these data have not been immediately informative regarding HLA genotype. We describe
HLAminer, a computational method for identifying HLA alleles directly from shotgun sequence datasets (http://www.
bcgsc.ca/platform/bioinfo/software/hlaminer). This approach circumvents the additional time and cost of generating
HLA-specific data and capitalizes on the increasing accessibility and affordability of massively parallel sequencing.
Background
Due to its central role in adaptive immunity, human leuko-
cyte antigen (HLA) is implicated in wide ranging areas of
medicine, from infectious disease and vaccinology to can-
cer, autoimmunity, aging and regenerative and transplanta-
tion medicine [1-7]. The HLA locus is the most
polymorphic region of the genome with over 5,000 variant
HLA-class I allelic sequences catalogued to date. This
genetic heterogeneity is the principal challenge to HLA
typing methodologies, and it is the reason why this region
has remained largely opaque to analysis by next-generation
sequencing (NGS) platforms. Conventional sequence-based
HLA typing approaches, the most recent of which exploits
the sequence throughput of the Illumina MiSeq [8] and
relatively long sequence reads of the 454 NGS platform [9],
are targeted assays that rely on amplification of hypervari-
able sub-regions of these loci and variant detection within
these amplicons. As such, HLA calls are based on sequence
information that is not as comprehensive as for shotgun
datasets, and must be generated de novo for each subject.
The widespread uptake of large-scale genome, exome and
transcriptome shotgun sequencing approaches for biome-
dical research, and now for clinical use, prompted us to
explore the utility of these types of NGS data sets for HLA
typing. The need has been for a solution to the problem of
managing the many millions of short sequence reads NGS
technologies produce, managing the many thousands of
reference allele sequences, and integrating all of these data
in a manner that maximally informs HLA content. Here
we present a method for HLA allele prediction from next-
generation shotgun sequence datasets. We focus on data
generated from the Illumina platform, from which most
sequence data are currently derived worldwide. Impor-
tantly, HLA allele assignments from shotgun datasets can
not be derived from standard alignment-based interpretive
methods for the simple reason that the extant genome
reference sequences [10,11] on which these methods rely
do not provide any useful representation of HLA allelic
diversity. Therefore, we have developed a computational
pipeline that derives HLA allele predictions by targeted
assembly of shotgun sequence data and comparison to a
database of reference allele sequences. Our solution allows,
for the first time, application of the power of NGS to the
interrogation of one of the most important and complex
sets of human genes. Our method is scalable, such that it
will provide utility in extracting HLA information even
from very large sequence data sets, such as those currently
being compiled by various international consortia [12-15].
Materials and methods
Library construction and sequencing
Written informed consent was obtained from all donors
and samples were collected following assessment of tissue
specimens by a pathologist according to standardized
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operating procedures, immediately following surgical
resection. Library construction and Illumina sequencing
were performed as previously described for RNA-Seq [16]
and whole genome shotgun (WGS) [17]. For the colorectal
cancer (CRC) RNA-Seq study, four lanes of 100-nucleotide
paired-end sequences were obtained for each of the two
pools, providing an average of 5 million paired reads per
sample. For WGS, approximately 430 million paired 100-
nucleotide WGS reads (approximately 30× depth coverage
human genome) from normal and tumor samples from
four diffuse large B cell lymphoma patients were processed
[17]. The sequencing data from the CRC study have been
submitted to the NCBI Sequence Read Archive [18] under
accession number SRP010181. A file describing the sample
libraries is available at [19].
Exome capture libraries were prepared using the SureSe-
lect system (Agilent) according to the manufacturer’s
instructions. Approximately 30 million (normal samples)
and 120 million (normal plus tumor samples)
100-nucleotide exon capture paired-end sequence reads
were generated from three ovarian cancer patients whose
HLA alleles were verified by PCR-based methods. Verifica-
tion of HLA allele predictions was accomplished by PCR
amplification of exons 2 and 3 from HLA-I A, B and C, fol-
lowed by capillary sequencing as previously described [20].
IMGT/HLA sequences
HLA coding DNA sequence (CDS) and genomic
sequence databases from release 3.3.0 and 3.4.0 were
obtained, respectively, from [21]. HLA-I exon 2 and 3
concatenated sequence FASTA files were prepared using
exon coordinates available from the flat file database
(EMBL format) released by IMGT [22]. For HLA allele
predictions from RNA-Seq data, we used concatenated
exons 2 and 3 as sequence targets for assembly using
the TASR assembly tool [23]. For predictions from gen-
ome and exome NGS data, we used HLA-I genomic
sequences from major genes A, B and C.
Computational HLA allele predictions by targeted read
assembly
HLA CDS or genomic sequences from IMGT/HLA
(sequence targets) are read by TASR (default options used
with -i 1), creating a hash table of every possible
15-nucleotide word (k-mers) encountered. NGS data sets
are interrogated for the presence of one of these k-mers in
5’ (on either strand) and candidate reads recruited.
Recruited reads seed the assembly in a manner analogous
to that of SSAKE [24]. Only sequence contigs equal to or
larger than a user-determined length (200 nucleotides
chosen for this study) are considered for further analysis.
Reciprocal BLAST [25] (v.2.2.22 with options -a 8 -F F -p
blastn -m 7) alignments are performed between the contig
and HLA CDS or genomic sequence databases depending
on the read source (RNA-Seq or WGS and exon capture),
parsed at runtime using PERL Bio::SearchIO modules and
summarized. HLAminer parses these alignment files and
generates a score and probability for each putative HLA
coding variant identified from sequence contigs. Briefly,
for each assembled contig, best BLAST HLA alignments
are reported, tracking the sequence identity over the align-
ment portion, as well as over the length of the contig.
Contigs are organized by increasing number of HLA
sequences they co-characterize best, listing all possible ex-
equo best hits and tracking HLA sequences that, recipro-
cally, best identify each contig. For each putative HLA, a
score SHLA is calculated as the sum of score computed for
each contig aligning to it. Individual contig scores factor in
the contig depth of coverage, length and percent sequence
identity, such that a score reflects the number of bases
aligned to a particular HLA allele. A reciprocal best hit
where a given HLA aligns best to a given contig doubles
the score for the identified HLA sequence:
SHLA =
n∑
Contig=1
ScoreContig = size∗depth∗%sequence identity
For any given contig, the probability of characterizing
a single HLA allele by chance is equal to the inverse
proportion of HLA sequences in the sequence database.
And since shorter contigs may not capture sufficient
bases to characterize any one type unambiguously, the
probability P that a contig characterizes one or another
HLA type is mutually exclusive such that:
PContig1 is HLAx =
∑
PHLA
The expect value (Eval) of each computationally deter-
mined HLAx, EvalHLAx, is calculated as:
EvalHLAx = (PContig1 is HLAx
∗PHLAx is Contig1)
∗(PContig2 is HLAx
∗PHLAx is Contig2 )
∗ . . .∗ (PContigx is HLAx
∗PHLAx is Contigx)
since individual contig probabilities and reciprocal
best hits are independent events. A short list of HLA
allele groups (for example, A*02) and protein coding
alleles (for example, A*02:01), sorted by decreasing
score, are catalogued for each major HLA gene. When
separate contigs characterize the same types, only the
types that overlap are reported, unless the non-overlap-
ping ones are characterized by additional, distinct contig
(s). In addition, we summarize ambiguous HLA alleles
using the P designation, when applicable.
Simulated data sets
In separate experiments, we removed HLA CDS, exonic
regions and genes from 15K randomly selected Ensembl
[26] transcripts, approximately 220K exon regions [27]
(SureSelect Target Enrichment, Agilent Technologies,
Inc. [28] and the HuRef genome [11]). For each data
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type, we randomly generated 20 sets of six (2 × A, 2 ×
B, 2 × C) HLA-I alleles (total of 120 alleles). In triplicate
experiments, we merged each set of six sequences with
HLA-less CDS, exon regions or HuRef, respectively, and
simulated at various depth of coverage 50-, 75-, 100- or
150-nucleotide paired-end reads with 0.5, 1, 2 or 3 error
using SAMtools [29] wgsim, and ran TASR and
BLASTN as described above. For the simulation from
direct read pair alignments, we used the simulated reads
described above and ran BWA [30] with defaults and
generated HLAminer predictions from SAM files.
Assessment metrics
We define the sensitivity as a proportion, that is, the
number of HLA allele groups or protein coding alleles
detected over the sum of distinct groups or protein cod-
ing alleles randomly chosen for the simulation or pre-
dicted by PCR, when applicable. The ambiguity rate is
the proportion of all ambiguous predictions per total
allele groups or protein coding alleles predicted. Ambig-
uous predictions arise when HLA allele groups or pro-
tein coding gene names differ despite having an
identical score and probability. The specificity is defined
as a proportion of number of groups or alleles predicted
accurately divided by the total number of groups or
alleles detected, respectively.
HLA typing
HLA class I alleles were predicted directly from the RNA-
Seq data as described [20]. Briefly, genomic DNA was
extracted from patient granulocytes, and exons two and
three from HLA class I genes (A, B, and Cw) were ampli-
fied by PCR [31]. PCR amplicons were cloned and
sequenced using an ABI 3730XL instrument, according to
standard procedures. Clone sequences were assembled
using Phred/Phrap/Consed [32]. The resulting sequence
data were aligned against all available exon 2 and 3
nucleotide sequences from the 3.1.0 release of the IMGT/
HLA database [22] using ClustalW [33]. Protein coding
allele assignments [34] were based on high-quality exact
or synonymous matches at informative nucleotide
positions.
Results and discussion
To maximize the performance of HLAminer with short
read data, we implemented stringent, localized, de novo
assembly of sequence reads prior to alignment (Figure 1,
left). Direct alignment of reads to reference alleles is
also supported (Figure 1, right), but at the present time
we find this modality has modest utility due to current
limitations on read length. HLAminer predictions are
arranged by HLA gene (for example, HLA class I A, B
and C) and for each, putative alleles are ranked by high-
est scoring HLA protein coding alleles. A confidence
value reflects the likelihood of each prediction (expect
value) on a log10 scale. A sample output from HLAmi-
ner is shown (Table 1).
For initial evaluation of HLAminer we relied on simu-
lated data sets, which allowed us to determine the influ-
ence on performance of sequencing parameters such as
depth of coverage, sequence read length, and sequence
error. We produced simulated data sets for each of the
three formats, RNA-Seq, WGS and exome, by taking
reference sequences (Ensembl transcripts, the HuRef
genome, and hg19 exon capture regions, respectively)
and substituting HLA-I A, B and C sequences with two
randomly chosen alleles of HLA-I A, B and C. From
these modified references we generated faux sequence
reads. For each sequence format, 20 such data sets were
generated and these were queried in triplicate, yielding a
total of 360 allele predictions per condition tested. The
sensitivity, specificity and ambiguity of HLA class I allele
prediction was evaluated by comparing the highest-scor-
ing HLAminer predictions to the randomly selected
alleles. By ambiguity we mean the prediction of multiple,
equally probably alleles.
HLA nomenclature (for example, HLA A*02:01)
defines the digits immediately following the asterisk as
the allele group (two-digit resolution, formerly referred
to as supertype) and the next set of digits (those follow-
ing the semicolon, often referred to as four-digit resolu-
tion) as the individual protein coding allele [34]. Further
separators and digits are sometimes used to describe
allelic variants that contain silent nucleotide differences.
Using simulated data, we found that at the level of HLA
allele groups, RNA-Seq data provided high sensitivity
and specificity (each >95.7%) with a low ambiguity
(<4.5%), even at relatively low coverage (<5 million total
read pairs) (Figure 2; Additional file 1). Likewise, WGS
provided high sensitivity and specificity (each >97.3%)
and no observable ambiguity (0.0%) for prediction of
allele groups, but required substantially higher sequence
depth, on the order of 400 million paired reads, to
achieve this (Figure 2; Additional file 1). This is the
equivalent of approximately 30× genome coverage with
100-nucleotide reads. For both RNA-Seq and WGS
data, predictions at the level of individual protein coding
alleles showed very similar sensitivity and specificity to
that observed for allele group predictions, but ambiguity
levels increased to approximately 30% (Figure 2; Addi-
tional file 1). Our expectations for HLA allele prediction
from exome data were low, because allelic diversity of
HLA coding sequence tends to have limited representa-
tion in standard capture reagents. For example, the Agi-
lent SureSelect system that we use at our center
contains 36 120-nucleotide RNA probes targeting the
HLA class I region of hg19. Still, we included evaluation
of this data type for the purpose of completeness, and
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with the understanding that a variety of HLA alleles
could possibly be captured by imperfectly matching
probes of this length. Our simulations revealed that
exome data did in fact show some modest utility for
HLA prediction, at least at the allele group level. For
allele group prediction, high specificity (92.8%) and low
ambiguity (4.7%) could be achieved at low coverage
(40 million read pairs); however, considerably higher
coverage was necessary to increase sensitivity, and even
at very high exome coverage (240 million read pairs)
sensitivity never approached that observed for the other
data types. By comparison, for RNA-Seq, 5 million and
3 million 100-nucleotide RNA-Seq read pairs are
required for 95% sensitivity and specificity, respectively.
For WGS, 427 million and 57 million 100-nucleotide
read pairs are needed for 95% sensitivity and specificity,
respectively. Under the conditions tested, exome data
did not provide such high levels of detection and
prediction accuracy at any read depth and performance
for predicting individual protein coding alleles from
exome data was uniformly poor (Figure 2).
Overall, from simulation, RNA-Seq datasets provided
the greatest utility for HLA prediction. This may be due,
in part, to lower representation in RNA-Seq data of off-
target regions, such as the minor HLA class I genes, pseu-
dogenes, and HLA class II genes, compared to genome or
exome data, where these regions would be expected to
have approximately equal representation as the class I
alleles of interest, A, B and C. The stark contrast in HLA-
miner predictions derived from RNA-Seq compared to
WGS or exome capture highlights intrinsic properties of
these datasets and their value for computational HLA pre-
dictions. Functional HLA-I alleles are expressed on all
nucleated cells, and despite possible amplification biases in
the RNA-Seq library construction protocol, the high abun-
dance of HLA-I transcripts is such that relatively low
Figure 1 Computational predictions of HLA-I from shotgun data by targeted assembly (left) or read alignment (right). For targeted
assembly, NGS reads having their first fifteen 5’ bases matching one of HLA CDS (RNA-Seq) or genomic (WGS/exon capture) sequences are
recruited and assembled de novo with TASR. Resulting sequence contigs are aligned against a database sequence of all predicted HLA CDS
(RNA-Seq) or genomic sequences (WGS/exon capture), tracking best HLA hit(s). Reciprocal best alignments are considered in the same manner.
Putative allele assignments from shotgun datasets (HLAminer) are informed by contig length, depth of coverage and similarity to reference
sequences, when applicable. The probability of each prediction being correct is estimated by determining the probability of that prediction
being observed by chance.
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depth of sequencing is needed for robust predictions
(approximately 5 million). On the other hand, non-func-
tional (null) HLA alleles that are present in the genome
(but transcriptionally silent) can confound HLA prediction
from WGS or exome capture data, since the functional
alleles and null alleles are equally represented in these data
types. HLAminer has the functionality to report predic-
tions from null alleles, if desired.
We explored further the effects of read length (up to
150 nucleotides) and sequencing errors (up to 3%) with
RNA-Seq data. Not unexpectedly, performance
improved with increasing read length and decreasing
base error (Table 2). Reads with length less than 75
nucleotides and error rates higher than 1% significantly
impacted performance for prediction of individual pro-
tein coding alleles, but prediction of allele groups
remained robust (Table 2).
Next, we evaluated the performance of HLAminer with
real shotgun datasets, including RNA-Seq data from 16
CRC libraries (RL Warren, DJ Freeman, P Watson, RA
Moore, EA Allen-Vercoe, RA Holt, manuscript sub-
mitted), WGS and RNA-Seq from four lymphoma libraries
[17] and exon capture data from three ovarian cancer
libraries (Figure 2; Additional file 1). HLA predictions
were compared to results from these same subjects
obtained from standard PCR and capillary sequence-based
typing [20]. Results mirrored those obtained from simu-
lated data. For all data types, prediction of allele groups
was more reliable than prediction of individual protein
coding alleles. For prediction of allele groups, the CRC
RNA-Seq data yielded predictions with highest sensitivity
and specificity (>96.5%) and low ambiguity (<2.4%), even
at low sequence depth (approximately 5 million pairs per
sample). From a total of 81 HLA allele groups predicted
by HLAminer on the CRC cohort shotgun data only a
single allele group prediction conflicted with PCR-based
typing results (Additional file 2). For WGS and exome
data, high sensitivity and specificity could also be achieved,
but only at much higher depth of coverage. For all data
types, the ambiguity associated with prediction of indivi-
dual protein coding alleles were higher than for prediction
of allele groups, with predictions from exome data sets
more significantly impacted than predictions from WGS
or RNA-Seq data sets. HLAminer predictions were also
benchmarked on low-coverage 100-nucleotide WGS data
from 20 individuals of the 1000 Genomes cohort [15].
HLA class I allele predictions obtained from these same
HapMap samples by the targeted PCR method of Erlich
and colleagues have been previously published [9]. Apply-
ing HLAminer to this data set, allele group sensitivity and
specificity of 86.7 ± 15.9% and 86.3 ± 16.1% were achieved
(Additional file 3), despite the relatively low number of
genome shotgun reads processed (mean ± standard devia-
tion of 361.2 ± 80.9 million. Further, our results from
these 1000 Genomes samples are consistent with those we
obtained from the diffuse large B cell lymphoma control
normal tissue (sensitivity and specificity of 68.8 ± 31.5%
and 71.3 ± 21.8%) and tumor tissue (sensitivity and specifi-
city of 75.0 ± 20.4% and 87.5 ± 14.4%) WGS datasets, for
which substantially higher sequence coverage was available
(approximately 1.1 billion reads per sample). As discussed,
the data type availability (WGS) and the lower depth of
Table 1 Output from HLAminer HLA class I predictions from a CRC patient 100-nucleotide RNA-Seq sample
Allelea Scoreb Expect value (Eval) Confidence (-10 × log10(Eval))
HLA-Ac
Predictiond 1 - A*02
A*02:01P 64038.03 1.63E-06 57.9
Prediction 2 - A*11
A*11:01P 5463.99 5.30E-09 82.8
HLA-B
Prediction 1 - B*27
B*27:05P 64579.61 2.67E-18 175.7
Prediction 2 - B*07
B*07:02P 56662.08 6.63E-12 111.8
HLA-C
Prediction 1 - C*07
C*07:02P 49419.33 5.23E-08 72.8
Prediction 2 - C*02
C*02:02Pe 20466.00 6.64E-16 151.8
C*02:21e 20466.00 6.64E-16 151.8
aHLA protein coding alleles validated by PCR are shown in bold face. bThe protein coding allele predictions are arranged by decreasing score from most to less
likely. cMost likely HLA class I allele groups and protein coding alleles (Confidence (-10 × log10(Eval)) ≥ 20 Score ≥ 1,000) for each gene. dThe prediction rank
factors in the maximum score for each predicted allele. eAmbiguity arises when two or more HLA allele group or protein coding alleles have the same score (for
example, C*02:02P and C*02:21).
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coverage (10- to 20-fold) are both limiting factors for
HLAminer predictions.
HLAminer can evaluate reads by direct alignment
(Figure 1, right). However, with Illumina read lengths
currently ranging from 100 to 150 nucleotides, this
approach has limited utility at the present time. At best
we observed 80.0 ± 3.5% sensitivity and 78.2 ± 2.8% spe-
cificity (mean ± standard deviation; Figure 2, top panel;
Additional file 1).
Regardless of input data, HLAminer predictions for
HLA allele groups (two-digit resolution) are more robust
than for HLA protein-coding alleles (four-digit resolution)
(Figure 2; Additional file 1). Both the sensitivity and speci-
ficity of four-digit allele predictions are reduced relative to
their two-digit counterparts, but changes to the ambiguity
of predictions are more pronounced. For example, with 5
million × 100-nucleotide simulated RNA-Seq read pairs,
four-digit predictions show a 8.9% decrease in sensitivity,
8.2% decrease in specificity, and a 31.9% increase in ambi-
guity, compared to two-digit predictions. This is because
HLA coding alleles often differ by only a single base. In
contrast to conventional HLA genotyping methods where
sequence analysis is restricted to HLA amplicons, a target
of reduced complexity compared to shotgun sequence
data, HLAminer interrogates the full diversity of sequence
information in whole transcriptome, whole genome or
whole exome datasets. Here, single base differences can be
more easily missed due to factors such as low or unequally
distributed sequence coverage and base errors. Thus, the
performance of HLAminer for robust four-digit HLA
allele calls is a limitation of the current data sets and per-
formance is expected to improve as sequencing
Figure 2 HLAminer performance. HLA allele group and protein coding allele predictions derived from targeted read assembly (black symbols)
or direct read alignment (grey symbols) of simulated 100-nucleotide RNA-Seq, WGS and exon capture (ExCap) datasets were compared to
original, spiked-in, HLA sequences and performance metrics evaluated (ambiguity, sensitivity and specificity represented by circle, triangle and
square symbols, respectively). HLAminer predictions were also obtained from targeted assembly of colorectal cancer (CRC; blue symbols),
lymphoma (DLBCL; red, orange and yellow symbols), 1000 Genomes (1KG; green symbols) and ovarian cancer (OV; violet and magenta symbols)
patient tumor (T) and/or matched normal (N) shotgun datasets and compared to PCR-based HLA types to calculate performance metrics.
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technologies evolve to offer greater accuracy and read
length at reduced cost.
Conclusions
HLAminer is the implementation of a strategy for auto-
mated HLA typing directly from NGS data sets. It is a
fundamentally different approach compared to conven-
tional methods that all rely on first amplifying HLA
genes. The identification of allelic variants from an indi-
vidual NGS data set by simple sequence search or align-
ment is precluded by the complexity of the locus, the
massive allelic diversity in the population and limitations
of short sequence reads to adequately capture these var-
iations. The option of typing, retrospectively, existing
cohorts for which NGS data have already been gener-
ated is enabling, particularly for large community
resource projects [12-15]. In this context, the HLA info
is value-added, as no additional cost is necessary to
generate further HLA specific data from an existing data
set. The method can also be applied prospectively. In
fact, it may turn out to be the case that it is most effi-
cient to do all HLA typing by shotgun sequencing, since
these types of data sets are maximally informative and
are becoming routine to generate.
It is recognized that certain HLA allele combinations are
common in certain populations, presumably due to link-
age disequilibrium [35]. For example the combination of
HLA-I A*01; C*07; B*08 is common in some western Eur-
opean populations. These conserved extended haplotypes
are not yet well represented in HLA databases, but in
future we will explore the possibility of using this type of
information to further improve computational HLA typ-
ing. We also expect to extend our approach to prediction
of HLA class II alleles. HLAminer is available for public
use [36].
Abbreviations
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Table 2 Effect of read length and base error on HLAminer predictions from targeted assembly of simulated RNA-Seq
dataa
HLA allele
resolution
Base error (%) Read length
(nucleotides)
Sensitivity (mean ± SD%) Specificity (mean ± SD%) Ambiguity(mean ± SD%)
Two-digit 1.0 50 13.62 ± 2.80 92.86 ± 10.10 19.06 ± 16.53
75 62.32 ± 3.62 90.27 ± 3.28 8.93 ± 2.67
100 95.72 ± 0.53 96.31 ± 0.02 4.46 ± 3.84
150 97.97 ± 2.80 95.73 ± 3.63 0.00 ± 0.00
Two-digit 0.5 100 93.04 ± 4.60 96.39 ± 1.44 2.91 ± 1.69
1.0 95.72 ± 0.53 96.31 ± 0.02 4.46 ± 3.84
2.0 64.64 ± 4.79 96.13 ± 1.43 13.40 ± 3.02
3.0 6.67 ± 2.51 100.00 ± 0.00 8.59 ± 8.34
Four-digit 1.0 50 7.78 ± 1.92 60.51 ± 20.02 27.78 ± 4.81
75 51.94 ± 2.93 77.36 ± 5.44 37.38 ± 11.16
100 86.84 ± 1.75 88.13 ± 1.41 36.32 ± 4.76
150 93.33 ± 3.63 93.07 ± 2.91 22.87 ± 2.40
Four-digit 0.5 100 84.72 ± 5.42 89.65 ± 2.25 24.03 ± 3.00
1.0 86.84 ± 1.75 88.13 ± 1.41 36.32 ± 4.76
2.0 56.94 ± 1.73 87.49 ± 4.77 39.14 ± 5.73
3.0 4.44 ± 2.10 68.69 ± 17.03 37.22 ± 25.62
aIn triplicate experiments, 5 million read pairs 50, 75, 100 or 150 nucleotides in length (top) and 100-nucleotide read pairs having 0.5, 1, 2 or 3% errors (bottom)
were randomly generated from 20 sets of transcripts, each containing 6 randomly chosen reference HLA alleles. HLAminer predictions derived from targeted
read assembly were compared to each reference set and the performance of HLAminer was assessed by measuring the specificity, sensitivity and ambiguity. SD,
standard deviation.
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